Search Results 1651-1660 of 21425 for anti-TNF drugs

1. A Trial to Evaluate the Effectiveness, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis - Mayo Clinic

   Drugs & Supplements A-Z · Health Books · Healthy ... treatment with more than 1 oral PAH-approved therapy or any parenteral therapy. ... anti-fibrotic drug within 4 ...

2. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Stage 3 Liver Fibrosis - Mayo Clinic

   Participants taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 ...

3. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Cirrhosis - Mayo Clinic

   Participants taking anti-diabetic, anti-obesity, or anti-dyslipidemic medications must have been on stable regimens for at least 3 months (12 weeks) (6 ...

4. Ripretinib (Oral Route) Description and Brand Names - Mayo Clinic

   Ripretinib is used to treat gastrointestinal stromal tumor (GIST) in patients who have received treatment with at least 3 other medicines (eg, imatinib).

5. Blood and Marrow Transplant Research Program - Transplant Research Center - Mayo Clinic Research

   Develop novel treatment approaches of GVHD; Test established and state-of-the-art GVHD treatment regimens, such as anti-thymocyte globulin (ATG), post ...

6. A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   By condition, treatment or drug ... anti-PD1, anti-PDL1 or anti-CTLA4 antibodies. ... Patients under chronic treatment with systemic corticosteroids or other ...

7. A Study to Evaluate Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers - Mayo Clinic

   - For Cohorts 2A and 2B: prior anti-HER2 therapies - For Cohorts 1E, 1F, 1G, 2A: Prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an ...

8. Immune Globulin (Intramuscular Route, Intravenous Route, Subcutaneous Route) Description and Brand Names - Mayo Clinic

   Immune globulin injection belongs to a group of medicines known as immunizing agents. ... Drugs & Supplements; Immune Globulin (Intramuscular Route, Intravenous ...

9. A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer - Mayo Clinic

   Any previous treatment with systemic anti cancer immunotherapy, including but not limited to anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents. For Part 1 ...

10. Neuroregeneration - Center for Regenerative Biotherapeutics - Mayo Clinic Research

    Innovative, paradigm-shifting strategies are required to advance treatment of neurological injury. The neuroregeneration research at Mayo Clinic is at the ...